Quince Therapeutics, Inc.QNCXNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank25
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-54.74M
↓ 24% vs avg
Percentile
P25
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
$-44.27M
Historical baseline
PeriodValueYoY Change
TTM$-54.74M-52.1%
2024$-35.98M-34.2%
2023$-26.82M+47.4%
2022$-50.99M+43.3%
2021$-89.97M-14.5%
2020$-78.56M-101.5%
2019$-38.98M-223.0%
2018$-12.07M-16.9%
2017$-10.32M-